Company News • Endpoint Arena

News Updates

Thu, May 21, 2026

1 updates

12:30 PM

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

tevapharm.com

Mon, May 18, 2026

2 updates

8:30 AM

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

tevapharm.com

8:00 AM

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

tevapharm.com

Mon, May 4, 2026

1 updates

4:30 PM

Teva to Present at the BofA Securities Health Care Conference

tevapharm.com

Thu, Apr 30, 2026

1 updates

8:30 AM

Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets

tevapharm.com

Wed, Apr 29, 2026

2 updates

7:00 AM

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

tevapharm.com

6:30 AM

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

tevapharm.com

Wed, Apr 15, 2026

1 updates

8:00 AM

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

tevapharm.com

Tue, Apr 14, 2026

1 updates

8:00 AM

Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

tevapharm.com

Mon, Mar 30, 2026

1 updates

8:00 AM

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

tevapharm.com

Thu, Mar 19, 2026

2 updates

4:30 PM

Teva Releases Q1 2026 Aide Memoire

tevapharm.com

4:30 PM

Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

tevapharm.com

Tue, Mar 3, 2026

1 updates

5:00 PM

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

tevapharm.com